Open Access Open Access  Restricted Access Subscription Access

Understanding Ganglionic Stimulants and Their Role in Drug Action

Muralinath E., Jayinder Paul Singh. G, Pradip Kumar Das, Panjan Ghosh P., Kinsuk Das S, Kalyan C., Archana Jain, Guruprasad M.

Abstract


Medication that affects the autonomic ganglia is another way to influence the autonomic nervous system (ANS). They may function as ganglionic blockers or stimulants. Since ganglia-targeting medications typically have a wide range of side effects, the majority of these medications are no longer used clinically and are only significant historically. Instead, more focused, specifically acting medications that do not act on the ganglia have become available and have replaced the ganglia-targeting medications. Nicotinic receptor antagonists block the fast activity of the first group, while atropine-like drugs block the delayed action of the second category. Nicotine is an alkaloid that increases blood pressure and quickens heart rate by either activating sympathetic ganglia or paralyzing parasympathetic ganglia.


Full Text:

PDF

References


Solanto, M. V. (1998). Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behavioural brain research, 94(1), 127-152.

Belin, D., Jonkman, S., Dickinson, A., Robbins, T. W., & Everitt, B. J. (2009). Parallel and interactive learning processes within the basal ganglia: relevance for the understanding of addiction. Behavioural brain research, 199(1), 89-102.

Murphy, D. L., Andrews, A. M., Wichems, C. H., Li, Q., Tohda, M., & Greenberg, B. (1998). Brain serotonin neurotransmission: an overview and update with an emphasis on serotonin subsystem heterogeneity, multiple receptors, interactions with other neurotransmitter systems, and consequent implications for understanding the actions of serotonergic drugs. Journal of Clinical Psychiatry, 59(15), 4-12.

Ikemoto, S., Yang, C., & Tan, A. (2015). Basal ganglia circuit loops, dopamine and motivation: a review and enquiry. Behavioural brain research, 290, 17-31.

Conn, P. J., Battaglia, G., Marino, M. J., & Nicoletti, F. (2005). Metabotropic glutamate receptors in the basal ganglia motor circuit. Nature Reviews Neuroscience, 6(10), 787-798.

Horacek, J., Bubenikova-Valesova, V., Kopecek, M., Palenicek, T., Dockery, C., Mohr, P., & Höschl, C. (2006). Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS drugs, 20, 389-409.

Gershon, M. D., & Tack, J. (2007). The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology, 132(1), 397-414.

Wise, R. A. (1988). The neurobiology of craving: implications for the understanding and treatment of addiction. Journal of abnormal psychology, 97(2), 118.

Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., & Caron, M. G. (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature, 379(6566), 606-612.

Nutt, D. J., Baldwin, D. S., & Clayton, A. H. (2006). The role of dopamine and norepinephrine in depression and antidepressant treatment. Journal of Clinical Psychiatry, 67(Suppl 6), 3-8.


Refbacks

  • There are currently no refbacks.